Rivastigmin STADA
Rivastigmine transdermal patch for Alzheimer's dementia
Quick facts about Rivastigmin STADA
Key takeaways about Rivastigmin STADA
- One patch per day: Always remove the previous patch before applying a new one. Never use more than one patch at a time
- Treats Alzheimer's symptoms: Rivastigmine increases acetylcholine levels in the brain, helping to manage cognitive decline in mild to moderate Alzheimer's dementia
- Gradual dose increase: Treatment starts at 4.6 mg/24h and is gradually increased to a target dose of 9.5 mg/24h or 13.3 mg/24h as tolerated
- Rotate application sites: Apply the patch to a different area each day (upper arm, chest, or back) and do not reuse the same site within 14 days
- Three-day rule: If treatment is interrupted for more than three days, consult your doctor before restarting as the dose may need to be adjusted
What Is Rivastigmin STADA and What Is It Used For?
Rivastigmin STADA is a transdermal patch containing rivastigmine, a cholinesterase inhibitor prescribed for the treatment of mild to moderately severe Alzheimer's dementia in adults. It works by blocking the enzymes that break down acetylcholine in the brain, helping to improve memory, thinking ability, and daily functioning.
The active substance in Rivastigmin STADA is rivastigmine, which belongs to a class of medications called cholinesterase inhibitors. In patients with Alzheimer's dementia, certain nerve cells in the brain die, leading to reduced levels of the neurotransmitter acetylcholine. Acetylcholine is a chemical messenger that enables nerve cells to communicate with each other, and its depletion is closely linked to the cognitive decline seen in Alzheimer's disease.
Rivastigmine works through a dual mechanism of action: it blocks both acetylcholinesterase and butyrylcholinesterase, the two enzymes responsible for breaking down acetylcholine. By inhibiting these enzymes, Rivastigmin STADA increases acetylcholine levels in the brain, thereby helping to reduce the symptoms of Alzheimer's disease. This dual inhibition is unique among cholinesterase inhibitors and may provide broader neuroprotective effects compared to selective inhibitors.
Alzheimer's disease is a progressive neurodegenerative condition that gradually affects memory, intellectual ability, behavior, and the capacity to perform daily activities. While rivastigmine does not cure or stop the progression of the disease, clinical studies have demonstrated that it can meaningfully slow cognitive decline and improve functional abilities in patients with mild to moderate Alzheimer's dementia. The transdermal patch formulation offers several advantages over oral forms, including more consistent drug delivery, fewer gastrointestinal side effects, and simpler administration for caregivers.
According to the World Health Organization (WHO), Alzheimer's disease accounts for 60-70% of all dementia cases worldwide, affecting an estimated 55 million people globally. Cholinesterase inhibitors like rivastigmine are recommended as first-line pharmacological treatment for mild to moderate Alzheimer's disease by major clinical guidelines, including those from the National Institute for Health and Care Excellence (NICE), the European Medicines Agency (EMA), and the American Academy of Neurology.
Rivastigmine is also approved in some countries for the treatment of mild to moderately severe dementia associated with Parkinson's disease. If you believe rivastigmine may be appropriate for a condition not described here, speak with your doctor for personalized medical advice.
What Should You Know Before Taking Rivastigmin STADA?
Before starting Rivastigmin STADA, inform your doctor about any heart conditions, stomach ulcers, urinary problems, seizures, respiratory conditions, liver problems, or low body weight. The patch must not be used if you are allergic to rivastigmine, carbamate derivatives, or any excipients.
Contraindications
You must not use Rivastigmin STADA in the following circumstances:
- If you are allergic to rivastigmine or any of the other ingredients in the patch
- If you have ever had an allergic reaction to a similar type of medication known as carbamate derivatives
- If you develop a skin reaction that spreads beyond the patch size, if an intensified local reaction occurs (such as blistering, increasing skin inflammation, or swelling), and if it does not improve within 48 hours after removing the patch
If any of these conditions apply to you, inform your doctor immediately and do not use Rivastigmin STADA transdermal patches. Allergic contact dermatitis from rivastigmine patches, while uncommon, can be a serious condition that requires medical evaluation. In such cases, your doctor will determine whether to switch to an alternative formulation or a different medication entirely.
Warnings and Precautions
Talk to your doctor before using Rivastigmin STADA if you have, or have ever had, any of the following conditions:
- Heart disease including irregular or slow heartbeat, QTc prolongation, family history of QTc prolongation, torsades de pointes, or low blood levels of potassium or magnesium
- Active stomach ulcer or a history of peptic ulcer disease
- Difficulty urinating including urinary obstruction or retention
- Seizures or a history of epilepsy or convulsions
- Asthma or severe respiratory problems including chronic obstructive pulmonary disease (COPD)
- Tremor or Parkinson's disease symptoms
- Low body weight as this may increase the risk of side effects
- Gastrointestinal reactions such as nausea, vomiting, and diarrhea, which can lead to dehydration if prolonged
- Impaired liver function which may affect how the drug is metabolized
If any of the above conditions apply to you, your doctor may need to monitor you more closely during treatment. Cholinesterase inhibitors like rivastigmine can increase gastric acid secretion, potentially exacerbating existing ulcers. They may also cause bradycardia (slow heart rate), which is particularly relevant in patients with cardiac conduction disorders or those taking medications that affect heart rate.
If you have not used a patch for more than three days, do not apply a new patch until you have spoken with your doctor. Treatment may need to be restarted at the lowest dose (4.6 mg/24 hours) to avoid potentially severe side effects from reintroducing the medication too quickly.
Pregnancy and Breastfeeding
If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, consult your doctor or pharmacist before using this medication. There is limited data on the use of rivastigmine during pregnancy, and the potential benefits must be weighed against the potential risks to the unborn child. Rivastigmin STADA should not be used during pregnancy unless clearly necessary as determined by your healthcare provider.
Breastfeeding is not recommended while using Rivastigmin STADA, as rivastigmine and its metabolites may pass into breast milk and could potentially affect the nursing infant. If you are breastfeeding, discuss with your doctor whether to discontinue breastfeeding or to discontinue the medication, taking into account the importance of treatment for the mother.
Driving and Operating Machinery
Rivastigmin STADA may cause fainting episodes, dizziness, or confusion, particularly when treatment is initiated or the dose is increased. Your doctor will advise you whether it is safe to drive or operate machinery based on your individual condition. Alzheimer's disease itself can impair the ability to safely drive or operate machinery, and the medication may further contribute to this impairment. Do not drive, operate machinery, or perform tasks requiring concentration if you experience dizziness, confusion, or feel faint.
How Does Rivastigmin STADA Interact with Other Drugs?
Rivastigmin STADA can interact with anticholinergic medications, metoclopramide, beta-blockers, muscle relaxants used during anesthesia, and drugs that prolong the QT interval. Always inform your doctor about all medications you are taking.
Drug interactions can alter how medications work or increase the risk of serious side effects. It is essential to inform your doctor or pharmacist about all prescription medications, over-the-counter drugs, herbal supplements, and vitamins you are currently taking or have recently taken. Below is a comprehensive overview of the most clinically significant interactions with rivastigmine.
| Interacting Drug | Effect | Severity | Recommendation |
|---|---|---|---|
| Metoclopramide | May cause rigidity, tremor, and extrapyramidal symptoms | Major | Avoid concurrent use |
| Beta-blockers (e.g., atenolol) | Additive bradycardia (slow heart rate), risk of syncope | Major | Use with caution, monitor heart rate |
| Anticholinergic drugs (e.g., dicyclomine, amantadine) | Reduced effectiveness of rivastigmine | Moderate | Avoid if possible; discuss alternatives |
| Muscle relaxants (during anesthesia) | Enhanced effects of succinylcholine-type muscle relaxants | Major | Inform anesthesiologist before surgery |
| QT-prolonging drugs | Additive risk of cardiac arrhythmias | Major | Use with caution, cardiac monitoring |
| Motion sickness drugs (diphenhydramine, scopolamine, meclizine) | Anticholinergic effects counteract rivastigmine | Moderate | Discuss alternatives with doctor |
Major Interactions
Metoclopramide should not be given at the same time as Rivastigmin STADA. The combination of these two medications can cause serious neurological problems including rigid muscles, involuntary movements, and tremor in the hands. Metoclopramide is commonly prescribed for nausea and vomiting, so if you experience these symptoms while on rivastigmine, your doctor should prescribe an alternative antiemetic.
Beta-blockers such as atenolol require careful monitoring when used together with rivastigmine. Both medications can slow the heart rate, and the combined effect may lead to significant bradycardia (abnormally slow heartbeat), which can cause fainting or loss of consciousness. Your doctor may need to monitor your heart rate regularly if both medications are necessary.
If you are scheduled for surgery, it is essential to inform your surgeon and anesthesiologist that you are using Rivastigmin STADA. Rivastigmine can enhance the effects of certain muscle relaxants used during general anesthesia, particularly succinylcholine-type agents, potentially leading to prolonged neuromuscular blockade.
Minor Interactions
Anticholinergic medications, including some drugs used for stomach cramps, Parkinson's disease, and motion sickness, may reduce the effectiveness of rivastigmine. Since rivastigmine works by increasing acetylcholine activity, drugs that block acetylcholine essentially work in the opposite direction. If you need treatment for these conditions, your doctor may recommend non-anticholinergic alternatives.
Rivastigmine can be used with food, drink, and alcohol without significant pharmacokinetic interactions. However, alcohol consumption is generally discouraged in patients with dementia as it may worsen cognitive symptoms and increase the risk of falls.
What Is the Correct Dosage of Rivastigmin STADA?
Treatment begins with a 4.6 mg/24h patch, increasing to a target dose of 9.5 mg/24h after at least 4 weeks if well tolerated. The dose can be further increased to 13.3 mg/24h. Apply one patch daily, remove after 24 hours, and rotate application sites.
Always use Rivastigmin STADA patches exactly as your doctor has prescribed. Do not change the dose without consulting your healthcare provider. The dosing strategy follows a gradual titration approach to minimize side effects while achieving optimal therapeutic benefit.
Remove the previous day's patch before applying a new one. Use only one patch per day. Never cut the patch. Press the patch firmly with your palm for at least 30 seconds.
Adults
| Phase | Patch Strength | Duration | Notes |
|---|---|---|---|
| Starting dose | 4.6 mg/24 hours | Minimum 4 weeks | Initial titration phase |
| Recommended dose | 9.5 mg/24 hours | Ongoing | If 4.6 mg is well tolerated |
| Maximum dose | 13.3 mg/24 hours | Ongoing | If 9.5 mg is well tolerated for minimum 4 weeks; for patients showing clinical benefit |
The usual recommended daily dose is Rivastigmin STADA 9.5 mg/24 hours. If this dose is well tolerated, your doctor may increase it to 13.3 mg/24 hours. Each dose increase should only be made after a minimum of 4 weeks at the current dose to allow adequate time to assess tolerability and clinical response.
Children
There is no relevant use of Rivastigmin STADA in the pediatric population for the treatment of Alzheimer's disease. This medication is not intended for use in children or adolescents under 18 years of age.
Elderly Patients
No specific dose adjustment is required for elderly patients beyond the standard titration schedule. However, elderly patients may be more susceptible to side effects, particularly gastrointestinal symptoms and weight loss. Your doctor will carefully monitor your response to treatment and adjust the dose accordingly. Patients with low body weight (under 50 kg) should be monitored particularly closely, as they may be at increased risk for adverse effects.
How to Apply the Patch
Proper application of the transdermal patch is essential for effective treatment. Follow these steps carefully:
- Choose the application site: Select a clean, dry, hairless area on the upper or lower back, upper arm, or upper chest (avoid the breasts). Ensure the skin is free from powder, oil, moisturizer, or lotion.
- Remove the previous patch: Gently peel off the old patch before applying the new one. If adhesive residue remains on the skin, wash the area with warm water and mild soap, or use baby oil to remove it.
- Open the sachet: Cut along the dotted line and remove the patch. Only open the sachet when you are ready to apply the patch.
- Peel off the protective liner: Remove one half of the protective film without touching the sticky side with your fingers.
- Apply and press firmly: Place the sticky side on the skin and remove the remaining protective film. Press the patch firmly with your palm for at least 30 seconds, ensuring all edges are properly sealed.
- Rotate sites: Change the application site each day. Do not apply to the same skin area twice within 14 days.
Bathing, swimming, and showering should not affect the patch. Make sure the patch does not come loose during these activities. Do not expose the patch to external heat sources (excessive sunlight, sauna, tanning bed) for extended periods, as heat may increase drug absorption.
Missed Dose
If you discover that you have forgotten to apply a patch, apply one immediately. You can apply the next patch at the usual time the next day. Do not apply two patches to compensate for a missed dose. If treatment has been interrupted for more than three days, do not apply a new patch without first consulting your doctor. In such cases, your doctor will likely restart treatment at the lowest dose (4.6 mg/24 hours) and gradually increase it again.
Overdose
If you accidentally apply more than one patch, remove all patches from the skin immediately and contact your doctor, as you may need medical supervision. Symptoms of overdose may include nausea, vomiting, diarrhea, high blood pressure, hallucinations, slow heart rate, and fainting. In cases of suspected overdose, contact your local poison control center or emergency services immediately.
If you stop using Rivastigmin STADA, symptoms of Alzheimer's disease may gradually worsen. Do not stop treatment without first consulting your doctor.
What Are the Side Effects of Rivastigmin STADA?
Common side effects include loss of appetite, dizziness, drowsiness, agitation, and urinary incontinence. Less common but more serious effects include heart rhythm disturbances, hallucinations, and stomach ulcers. Most side effects are temporary and improve as your body adjusts to the medication.
Like all medicines, Rivastigmin STADA can cause side effects, although not everybody gets them. Side effects are more likely to occur when starting treatment or when the dose is increased. They usually subside gradually as your body becomes accustomed to the medication. Remove the patch and contact your doctor immediately if you experience any serious side effects.
Side Effects from the Transdermal Patch
Common
- Loss of appetite
- Dizziness
- Agitation or drowsiness
- Urinary incontinence (inability to hold back urine)
Uncommon
- Heart rhythm disturbances (fast or slow heartbeat)
- Hallucinations (seeing things that are not real)
- Stomach ulcer
- Dehydration (fluid loss)
- Hyperactivity and restlessness
- Aggression
Rare
- Falls
Very Rare
- Stiffness in arms or legs
- Tremor in hands
Frequency Not Known
- Allergic reaction at the application site (blisters or skin inflammation)
- Worsening of Parkinson's disease symptoms (trembling, stiffness, shuffling gait)
- Pancreatitis (severe upper abdominal pain, usually with nausea and vomiting)
- Rapid or irregular heartbeat
- High blood pressure
- Seizures (convulsions)
- Liver function disorders (yellowing of skin or eyes, dark urine, unexplained nausea or fatigue)
- Elevated liver enzyme values
- Restlessness
- Nightmares
- Pisa syndrome (involuntary muscle contraction causing abnormal lateral bending of the body and head)
Additional Side Effects from Oral Rivastigmine
The following side effects have been observed with rivastigmine capsules or oral solution and may also occur with the transdermal patch:
Common (oral formulation)
- Excessive saliva production
- Decreased appetite
- Restlessness
- General feeling of being unwell
- Trembling or feeling confused
- Increased sweating
Uncommon (oral formulation)
- Irregular heartbeat (fast heart rate)
- Sleep difficulties
- Accidental falls
Rare (oral formulation)
- Seizures (convulsions)
- Intestinal ulcers
- Chest pain (may be caused by angina)
Very Rare (oral formulation)
- High blood pressure
- Pancreatitis
- Gastrointestinal bleeding (blood in stool or vomit)
- Hallucinations
- Esophageal tears (in patients with severe vomiting)
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed here. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Rivastigmin STADA?
Store Rivastigmin STADA in the original packaging to protect from light. Keep it out of the sight and reach of children. Do not use after the expiry date printed on the carton and sachet.
Proper storage of medication is essential to maintain its effectiveness and safety. Follow these storage guidelines carefully:
- Keep out of reach of children: Store this medication where children cannot see or reach it, as used patches still contain active medication that could be harmful if accidentally applied or ingested
- Check the expiry date: Do not use after the expiry date (EXP) stated on the carton and patch sachet. The expiry date refers to the last day of the stated month
- Store in original packaging: Keep the patches in their sealed sachets until ready for use, as they are light-sensitive
- No special temperature requirements: Store at room temperature; no refrigeration is needed
- Check integrity: Do not use a patch if it appears damaged or if the sachet shows signs of having been opened
Disposing of used patches: After removing a used patch, fold it in half with the adhesive side inward and press together. Place the used patch back in the sachet and keep it safely away from children. Wash your hands with soap and water after handling the patch. Do not touch your eyes with your fingers after handling the patch; if your eyes become red after handling, rinse immediately with plenty of water and contact your doctor if symptoms persist.
Do not dispose of medications via wastewater or household waste. Ask your pharmacist about proper disposal methods for medicines you no longer use. These measures help protect the environment.
What Does Rivastigmin STADA Contain?
The active ingredient is rivastigmine. The 4.6 mg/24h patch contains 9 mg rivastigmine (5 cm²), the 9.5 mg/24h patch contains 18 mg rivastigmine (10 cm²), and the 13.3 mg/24h patch contains 27 mg rivastigmine (15 cm²).
Active Ingredient
The active substance is rivastigmine. The amount of rivastigmine in each patch and the release rate differ by strength:
| Patch Strength | Rivastigmine Content | Patch Size | Release Rate |
|---|---|---|---|
| 4.6 mg/24 hours | 9 mg | 5 cm² | 4.6 mg per 24 hours |
| 9.5 mg/24 hours | 18 mg | 10 cm² | 9.5 mg per 24 hours |
| 13.3 mg/24 hours | 27 mg | 15 cm² | 13.3 mg per 24 hours |
Inactive Ingredients (Excipients)
The other ingredients of Rivastigmin STADA are:
- Backing film: Polyester film
- Drug matrix: Acrylate-based adhesive, acrylate-based copolymer containing butyl and methyl methacrylate (80:20)
- Adhesion layer: Silicone-based adhesive
- Protective liner: Fluorine-coated polyester film
- Printing: Black printing ink
Appearance and Pack Sizes
Each transdermal patch is a thin, semi-transparent patch consisting of three layers. The outside is translucent, white, and marked with "Rivastigmin" and the strength in black print. Each patch is individually packaged in a child-resistant, heat-sealed sachet. Packs are available in 7, 10, 30, 50, 60, or 90 patches, as well as multipacks of 60 (2x30), 90 (3x30), or 100 (2x50) patches. Not all pack sizes may be marketed in your country.
Frequently Asked Questions About Rivastigmin STADA
Rivastigmin STADA is a transdermal patch used to treat mild to moderately severe Alzheimer's dementia in adults. It contains rivastigmine, a cholinesterase inhibitor that increases acetylcholine levels in the brain. This helps to improve memory, cognitive function, and the ability to perform daily activities. It does not cure Alzheimer's disease but can slow the progression of symptoms.
Apply one patch daily to clean, dry, hairless skin on the upper or lower back, upper arm, or upper chest. Remove the previous day's patch first. Press the new patch firmly with your palm for at least 30 seconds. Rotate application sites daily, avoiding the same area within 14 days. To remove, gently peel off from one corner. If adhesive residue remains, wash with warm water and mild soap or use baby oil. Never use alcohol or nail polish remover.
The most common side effects include loss of appetite, dizziness, agitation or drowsiness, and urinary incontinence. These typically occur when starting treatment or increasing the dose and usually improve over time as the body adjusts. Less common but important side effects include heart rhythm disturbances, hallucinations, stomach ulcers, and dehydration. Contact your doctor if side effects are persistent or severe.
Yes, bathing, swimming, and showering should not affect the Rivastigmin STADA patch. Ensure the patch does not come loose during these activities. However, you should avoid exposing the patch to external heat sources such as excessive sunlight, saunas, or tanning beds for prolonged periods, as heat can increase the rate of drug absorption and potentially increase side effects.
If you have missed patches for up to three days, you can resume treatment at the same dose. However, if treatment has been interrupted for more than three days, do not restart on your own. Contact your doctor first, as they will likely need to restart treatment at the lowest dose (4.6 mg/24h patch) and gradually titrate back up. Restarting at a higher dose without proper titration can cause severe side effects including nausea, vomiting, and gastrointestinal disturbances.
No, Rivastigmin STADA does not cure Alzheimer's disease. It is a symptomatic treatment that helps manage the cognitive and functional symptoms by increasing acetylcholine levels in the brain. While it can slow cognitive decline and improve daily functioning for a period, the underlying neurodegenerative disease process continues. The treatment is most effective in the mild to moderate stages of the disease. Your doctor will regularly assess whether continued treatment remains beneficial.
References and Sources
This article is based on international medical guidelines, approved product information, and peer-reviewed research. All medical claims are supported by evidence level 1A (highest quality evidence).
- European Medicines Agency (EMA). Rivastigmine transdermal patch - Summary of Product Characteristics (SmPC). Last updated 2025. Available at: www.ema.europa.eu
- World Health Organization (WHO). Dementia Fact Sheet. 2023. Available at: www.who.int
- Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;4:CD001191. DOI: 10.1002/14651858.CD001191.pub4
- National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support. NICE guideline [NG97]. 2018, updated 2024. Available at: www.nice.org.uk
- Winblad B, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S14-S22.
- Cummings J, et al. Rivastigmine patch for Alzheimer's disease and Parkinson's disease dementia: A review. Expert Opinion on Pharmacotherapy. 2020;21(18):2235-2248.
- British National Formulary (BNF). Rivastigmine. BMJ Group and Pharmaceutical Press. 2025.
- Feldman HH, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57(4):613-620.
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians with specialist training in neurology, geriatric medicine, and clinical pharmacology. Our team follows international editorial standards and the GRADE evidence framework to ensure the highest quality of medical information.
All content undergoes multi-stage review by board-certified physicians with expertise in the relevant medical specialty. We follow evidence-based medicine principles and cite only peer-reviewed sources.
iMedic has no commercial funding from pharmaceutical companies. Our content is editorially independent and free from commercial influence. We do not accept advertising revenue from drug manufacturers.